Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
9.80 x 1 11.10 x 1
Post-market by (Cboe BZX)
10.66 +0.13 (+1.23%) 04/11/25 [NASDAQ]
9.80 x 1 11.10 x 1
Post-market 10.66 unch (unch) 17:34 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
10.14
Day High
10.84
Open 10.57
Previous Close 10.53 10.53
Volume 371,700 371,700
Avg Vol 526,050 526,050
Stochastic %K 22.50% 22.50%
Weighted Alpha +18.35 +18.35
5-Day Change -0.35 (-3.18%) -0.35 (-3.18%)
52-Week Range 4.26 - 16.97 4.26 - 16.97
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 356,396
  • Shares Outstanding, K 33,433
  • Annual Sales, $ 37,210 K
  • Annual Income, $ -26,390 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.85
  • Price/Sales 9.46
  • Price/Cash Flow N/A
  • Price/Book 4.90

Options Overview Details

View History
  • Implied Volatility 96.30% ( -13.73%)
  • Historical Volatility 69.98%
  • IV Percentile 86%
  • IV Rank 73.01%
  • IV High 131.49% on 04/29/24
  • IV Low 1.11% on 08/16/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 417
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 6,501
  • Open Int (30-Day) 6,202

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.10
  • Number of Estimates 1
  • High Estimate 0.10
  • Low Estimate 0.10
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +123.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.78 +9.00%
on 04/07/25
Period Open: 11.80
14.61 -27.04%
on 03/26/25
-1.14 (-9.66%)
since 03/11/25
3-Month
9.78 +9.00%
on 04/07/25
Period Open: 11.48
16.97 -37.18%
on 02/07/25
-0.82 (-7.14%)
since 01/10/25
52-Week
4.26 +150.23%
on 04/18/24
Period Open: 5.00
16.97 -37.18%
on 02/07/25
+5.66 (+113.20%)
since 04/11/24

Most Recent Stories

More News
Beta Bionics Announces Board Appointment of Gerard Michel

BBNX : 10.91 (+2.06%)
DCTH : 10.66 (+1.23%)
Delcath Systems - Super Growth Projections

Summary Delcath Systems (DCTH) shows strong technical buy signals, with a 53.41% gain since 1/25 and a 271.33% gain in the last year. The company focuses on liver cancer treatments, with its leading product...

DCTH : 10.66 (+1.23%)
News Movers: Today’s Hottest News That Could Move the Needle Tomorrow

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

BCLI : 0.7624 (-16.54%)
LASE : 2.65 (+3.92%)
PPBT : 2.50 (+3.31%)
BCTX : 4.35 (+8.48%)
STXS : 1.6600 (unch)
DCTH : 10.66 (+1.23%)
DMGGF : 0.1604 (+11.85%)
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 110.93 (+3.12%)
X : 40.06 (-1.98%)
MNDY : 240.81 (-1.17%)
TSLA : 252.31 (-0.04%)
KEY : 13.73 (-0.07%)
CMA : 51.04 (-0.51%)
HD : 353.86 (+0.07%)
SU : 33.45 (+3.85%)
ALC : 89.61 (+3.00%)
A : 102.71 (+2.76%)
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and...

DCTH : 10.66 (+1.23%)
Delcath Systems to Host First Quarter 2023 Results

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)
Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 10.66 (+1.23%)

Business Summary

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

See More

Key Turning Points

3rd Resistance Point 11.64
2nd Resistance Point 11.24
1st Resistance Point 10.95
Last Price 10.66
1st Support Level 10.26
2nd Support Level 9.85
3rd Support Level 9.56

See More

52-Week High 16.97
Fibonacci 61.8% 12.11
Last Price 10.66
Fibonacci 50% 10.61
Fibonacci 38.2% 9.12
52-Week Low 4.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.